

Public Health Link

From the Chief Medical Officer for Wales

Distribution:	As Appendix 1
From:	Chief Pharmaceutical Officer, Andrew Evans
Date:	15 April 2020
Reference:	CEM/CPhA/2020/20a
Category:	Important information for immediate action
Title:	Ibuprofen And Coronavirus (Covid-19)
For Action by:	<p>General Practitioners – Action as below.</p> <p>Dispensing General Practitioners – Ensure all working in your dispensary see this alert and a copy is held on your locum file – Action as below.</p> <p>Community Pharmacies – Action as below</p> <p>Hospital pharmacies – Action as below.</p> <p>Chief Pharmacists - Action as below.</p>
For Information:	See Annex 1 – Distribution List
What is this about:	Full details are set out below.
Why has it been sent:	For your information, action and to pass on to colleagues.

Issue:

The Commission on Human Medicines Expert Working Group on coronavirus (COVID-19) has concluded that there is currently insufficient evidence to establish a link between use of ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs), and contracting or worsening of COVID-19.

The attached alert provides further information.

A short information film which may be useful for patients can be found at:

<https://twitter.com/wghealthandcare/status/1240352116574732290?s=21>

Appendix 1

To: Chief Executives of Health Boards and NHS Trusts
Medical Directors of Health Boards
Nurse Directors Health Boards
Directors of Public Health
Hospital Principals and Chief Pharmacists
NHS Direct

To: **NHS Wales Shared Services Partnership to forward to:**

General Practitioners.

Dispensing General Practitioners – Ensure all working in your dispensary see this alert and a copy is held on your locum file.

Community Pharmacies.

Deputising services.

HB Prescribing Advisers.

Independent/Private clinics and Hospitals and Hospices throughout Wales.